


J.P.Morgan

Q3 2025 Medtech Licensing and Venture Report

October 2025

Fueled by

DEALFORMA 



Executive summary

Exit Potential: Medtech IPO and M&A remained active through Q3 2025

Medtech IPO and M&A activity increased through Q3 2025, surpassing full-year 2024 numbers. Venture investment, which started the year strong, weakened in the third quarter. Medtech licensing and R&D partnerships saw a smaller share of deal value in upfront payments despite a larger total announced deal value.

Here are a few highlights from our Q3 2025 report:

- **Medtech venture activity:** There were 67 venture rounds totaling \$2.9 billion in Q3 2025, bringing the 2025 year-to-date total to \$9.5 billion across 259 rounds.
- **Medtech licensing partnerships:** In Q3 2025, 21 medtech licensing partnership deals were announced, disclosing a total deal value of \$7.9 billion, with over \$126 million in upfront payments. The 2025 year-to-date total reached \$10.1 billion, with \$376 million committed upfront.
- **M&A:** 65 medtech M&A deals were announced in Q3 2025, totaling \$21.7 billion in upfront cash and equity.
- **IPOs:** Four medtech IPOs raised \$568 million on NASDAQ and NYSE in Q3 2025, bringing the 2025 year-to-date IPO volume to \$1.5 billion across seven offerings of \$15 million+ on U.S. exchanges.

J.P. Morgan is dedicated to your success. Our relationships, our capital, and our skilled team of bankers and specialists dedicated to the life sciences sector reflect our conviction in the pivotal contributions these clients are making to society, shareholders and employees alike.

Our bankers' expertise ranges from advising companies at the earliest stage of formation to leading complex M&A and capital markets transactions. Regardless of the size or stage of your company, we are prepared and equipped to advise and support you in meeting your strategic and financial objectives.

Thank you for taking the time to read our report. We look forward to working with you.

Kathryn McDonough
Head of Life Sciences, Innovation Economy
Commercial Banking
J.P. Morgan

Parameters

Medtech companies are defined as firms developing medical devices, diagnostics, therapeutic digital health and commercial research tools. Healthcare IT and payer/provider software are excluded. Clinical research organizations are also included where they are leveraging innovative research tools.

Therapy areas, development stages, modalities and deal structures are segmented per the DealForma database.


Financials are based on disclosed figures curated by DealForma. Multiple tranches of the same Series are counted as one together.

Deals are tracked globally unless otherwise noted.


Data as of Sept. 30, 2025

Q3 medtech venture funding up quarter over quarter, but down year over year

QUARTERLY MEDTECH VENTURE INVESTMENT VS. ANNUAL VENTURE DEAL COUNT¹



10-YEAR U.S. TREASURY YIELD VS. MEDTECH VENTURE DEPLOYMENT (INDEXED)^{1,2}




Medtech venture funding started the year strong yet had a weaker Q2 and Q3 in a challenging venture funding environment across all of healthcare and life sciences. \$2.9 billion was invested in Q3 2025 compared to \$3.1 billion in Q3 2024.

Despite Q3 being down slightly year over year, Medtech continues to attract meaningful interest from venture investors with \$9.5 billion raised across 259 rounds year-to-date.


Notes: ¹Financials based on disclosed figures. Data through Sept. 30, 2025. ²Medtech venture capital deployment is indexed to Q1 2020, where Q1 2020 = 100.

Large medtech investment rounds continued through Q3 2025

COUNT OF VENTURE INVESTMENT ROUNDS BY ROUND SIZE¹



COUNT OF R&D LICENSES BY DISCLOSED UPFRONT CASH AMOUNT¹




Q3 2025 continued a trend of large funding rounds in the medtech venture space. Of the 259 medtech venture rounds closed so far this year, 26 were \$100 million or greater, and an additional 28 surpassed \$50 million. Among the largest medtech venture rounds in Q3 2025 were the Lila Sciences Series A at \$235 million, Supira Medical's \$120 million Series E and SetPoint Medical's \$115 million Series D.

Medtech R&D partnership and licensing upfront payments remained steady, with one licensing partnership disclosing an upfront payment exceeding \$100 million through Q3 2025. There were no large upfront deals in Q3, however. Three more of the seven disclosed R&D licensing deals have crossed the \$10 million threshold, just one short of full-year 2024.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025.

Early-stage medtech venture rounds continued to lag late-stage activity through Q3 2025

MEDTECH SEED AND SERIES A VENTURE ACTIVITY VS. SERIES B+ VENTURE ACTIVITY¹




Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025.

Through Q3 2025, Series B+ rounds accounted for \$7.9 billion across 166 rounds. Seed and Series A rounds during the same period saw only \$1.6 billion invested across 93 rounds.

Notable Series A transactions in the space from Q3 2025 include Axon Therapies (\$32 million), as well as Luna Health (\$23 million).

Medtech companies in San Francisco and Boston attracted the most venture investment


MEDTECH VENTURE INVESTMENT BY GEOGRAPHY, 2024-2025 YTD¹



Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025.

Medtech licensing continues to place a larger share of deal value on contingent payments


MEDTECH R&D PARTNERSHIP AND LICENSING DEAL VALUE TOTALS AND UPFRONT CASH AS A PROPORTION OF DEAL VALUE¹




Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025.

Medtech M&A remained active in Q3 2025

MEDTECH M&A ACTIVITY^{1,2}




MEDIAN M&A UPFRONT CASH AND EQUITY^{1,2}



Medtech M&A activity accelerated in Q3 2025 with 65 transactions, the most active quarter since 2022. Those transactions totaled \$21.7 billion in upfront cash and equity, the second-highest quarterly value over the same period. Median M&A upfront payments rose to \$177 million.

The major driver of the spike in transaction value in Q3 2025 was Waters Corp's merger with Beckton Dickinson's Biosciences & Diagnostic Solutions business for approximately \$17.5 billion. Other notable transactions include Terumo Corp's acquisition of OrganOx for \$1.5 billion and ArchiMed Group's acquisition of ZimVie Inc. for \$730 million.


COUNT OF M&A DEALS BY ACQUIRED COMPANY TYPE^{1,2}



Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025. ²Medtech M&A with any buyer type, acquisition options and reverse mergers.

Year-to-date 2025 medtech IPO activity rose again to surpass full-year 2024

NASDAQ AND NYSE COMPLETED IPOS IN MEDTECH: TOTALS (\$B) AND COUNT^{1,2}



Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2025. ²Includes only NASDAQ and NYSE IPOs \$15 million and larger by completion date.

Chase, J.P. Morgan, JPMorgan, JPMorgan Chase, and Story by J.P. Morgan are marketing names for certain businesses of JPMorgan Chase & Co. and its affiliates and subsidiaries worldwide (collectively, "JPMC", "We", "Our" or "Us", as the context may require). The information in this content (website, article, event invitation or other form) does not represent an offer or commitment to provide any product or service. The views, opinions, analyses, estimates and strategies, as the case may be ("views"), expressed in this content are those of the respective authors and speakers named in those pieces, and/or the JPMC departments that publish the content and may differ from those of JPMorgan Chase Commercial Banking and/or other JPMC employees and affiliates. These views are as of a certain date and often based on current market conditions, and are subject to change without notice. Any examples used are generic, hypothetical and for illustration purposes only. Any prices/quotes/statistics included have been obtained from sources deemed to be reliable, but we do not guarantee their accuracy or completeness. To the extent indices have been used in this content, please note that it is not possible to invest directly in an index. This is not a product of the Research Department of J.P. Morgan Securities LLC. This information in no way constitutes research and should not be treated as such. Any information related to cybersecurity provided is intended to help clients protect themselves from cyber fraud, not to provide a comprehensive list of all types of cyber fraud activities nor to identify all types of cybersecurity best practices.

Copying, re-publishing, or using this material or any of its contents for any other purpose is strictly prohibited without prior written consent from JPMorgan. In preparing this material, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information that was acquired from public sources. Any mentions of third-party trademarks, brand names, products and services are for referential purposes only and any mention thereof is not meant to imply any sponsorship, endorsement, or affiliation unless otherwise noted. Notwithstanding anything to the contrary, the statements in this material are not intended to be legally binding. Any products, services, terms or other matters described herein (other than in respect of confidentiality) are subject to, and superseded by, the terms of separate legally binding documentation and/or are subject to change without notice.

The information in this content is not advice on legal, tax, investment, accounting, regulatory, technology or other matters. You should always consult your own financial, legal, tax, accounting or similar advisors before making any financial or investment decisions, or entering into any agreement for JPMC products or services. In no event shall JPMC or any of its directors, officers, employees or agents be liable for any use of, for any decision made or action taken in reliance upon, or for any inaccuracies or errors in or omissions from, the information in this content. We are not acting as your or any client's agent, fiduciary or advisor, including, without limitation, as a Municipal Advisor under the Securities and Exchange Act of 1934. JPMC assumes no responsibility or liability whatsoever to you or any client with respect to such matters, and nothing herein shall amend or override the terms and conditions in the agreement(s) between JPMC and any client or other person.

The information in this content does not include all applicable terms or issues, and is not intended as an offer or solicitation for the purchase or sale of any product or service. Our products and services are subject to applicable laws and regulations, as well as our service terms and policies. Not all products and services are available in all geographic areas or to all customers. In addition, eligibility for particular products and services will be determined by JPMC, including satisfaction of applicable legal, tax, risk, credit and other due diligence, and JPMC's "know your customer", anti-money laundering, anti-terrorism and other policies and procedures. Credit is subject to approval. Rates and programs are subject to change. Certain restrictions apply.

Products and services may be provided by banking affiliates, securities affiliates or other JPMC affiliates or entities. In particular, securities brokerage services other than those that can be provided by banking affiliates will be provided by appropriate registered broker/dealer affiliates, including J.P. Morgan Securities LLC and J.P. Morgan Institutional Investments Inc. Any securities provided or otherwise administered by such brokerage services are not deposits or other obligations of, and are not guaranteed by, any banking affiliate and are not insured by the Federal Deposit Insurance Corporation. Certain financial products and services are required by law to be provided only by licensed representatives and affiliates. Inquiries regarding such products and services will be referred to a licensed representative or a licensed affiliate. The information in this content is not an offer to sell, or solicit an offer to purchase, any securities by anyone in any jurisdiction in which such offer or solicitation is not authorized, or in which JPMC or the person making such an offer is not qualified to do so, or to anyone to whom it is unlawful to make such an offer or solicitation, or to anyone in any jurisdiction outside of the United States. Nothing in this content constitutes any commitment by JPMC to underwrite, subscribe for or place any securities, or to extend or arrange credit, or to provide any other product or service. JPMC contact persons may be employees or officers of any JPMC subsidiary or affiliate.

Any information requested on this invitation, page or other relevant registration form will be processed for the purposes of preparation and administration of this event. Providing the requested information will also assist us in ensuring that the event is properly tailored to meet the requirements of the attendees. By providing the information requested, you are consenting to your data being processed by employees and agents of JPMC as well as potential co-organizers for these purposes. You expressly consent to our use of your information in the manner described herein and in our privacy policy (www.jpmorgan.com/privacy).

Please note that any JPMC-hosted event or webinar that you register to attend may be recorded, and videos, photographs and other recordings may be taken, where you may be captured participating in the event. By providing the information requested on the registration form, you consent to the publication of such photographs, videos, recordings and/or likenesses (whether edited, adapted, modified or copied), and their use by us and those that we authorize, without prior notice or compensation, in any way which we may see fit now or in the future, including but not limited to, marketing and advertising. Further, you release JPMC and its employees and agents from all claims of every kind on account of such use. You also acknowledge and agree that the replay links, if any, will be shared with JPMC clients and prospects who were invited but did not register/attend, and also potentially to other third parties if the topics are relevant to them. If you do not agree with any statements in this paragraph, please make a member of our staff aware on the day of the event.

The statements made in this content or during this event, or provided in materials as part of this event, are proprietary to JPMC and are not intended to be legally binding. Any products and services described during these events are offered by JPMC subject to applicable laws and regulations and service terms.

We will provide reasonable accessibility accommodations brought to our attention.

Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: [https://www.jpmorgan.com/IBOR](http://www.jpmorgan.com/IBOR).

© 2025 JPMorgan Chase & Co. All rights reserved. JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A., organized under the laws of the U.S.A. with limited liability. Deposits held in non-U.S. branches, are not FDIC insured.